VM-26 as a second drug in the treatment of brain gliomas.
Twenty patients previously treated with surgical resection, radiation therapy, and a nitrosourea for malignant gliomas of the brain were given VM-26 as a second chemotherapeutic agent when evidence of tumor progression occurred. Thirty-five percent achieved an arrest or decrease of neurologic symptoms, with a median length of response (arrest and tumor regression) of 22 weeks.
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D005910:Glioma / Q000188:drug therapy*; D006801:Humans; D009607:Nitrosourea Compounds / Q000008:administration & dosage / Q000627:therapeutic use; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D013713:Teniposide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D013713:Teniposide; D011034:Podophyllotoxin